

An international investigator initiated trial to capture different approaches in the treatment of Haemophilia A Patients With FVIII Inhibitors

Estado Reclutando	Tipo de Participantes Sujetos incapaces de otorgar consentimiento	Rangos de Edad Menores de 18 , Mayores de 64 , Adultos (18-64 años)
Género Hombres	Fases Fase IV	Participantes esperados 101
Resultados Sin resultados	Bajo nivel intervención Si	Enfermedad rara Si
Cobertura geográfica Sin determinar	Ámbitos del ensayo profilaxis, tratamiento, seguridad, eficacia, farmacocinética, farmacogenética, farmacoeconómica	Terapia avanzada NO

Información

Identificador
2024-516741-39-00 (CTIS)

Cod. Protocolo
MOTIVATE

Transicionado 2019-003427-38

Área terapéutica
Enfermedades [C] - Hematología [C15]

Enfermedad investigada
Haemophilia A

Título Científico
MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A An International Low-Interventional Pragmatic

Investigator Initiated Trial

Justificación

No aportado

Objetivo Principal

The primary objective for Groups 1 and 2 is to evaluate ITI outcomes as determined by achievement of the following ITI criteria: 1. Inhibitor titre < 0.6 Bethesda units (BU)/mL for at least 2 consecutive measurements 2. FVIII recovery 66% of the predefined reference value of 1.5% international units (IU)/kg body weight (BW) 3. FVIII half-life 6 h The primary objective for Group 3 is to evaluate the annualised bleeding rate (ABR) compared with the ABR in Group 1 and Group 2.

Variables de Evaluación Primaria

The primary endpoint in Group 1 and Group 2 is to evaluate ITI outcome as determined by achievement of the following ITI criteria: 1. Inhibitor titre < 0.6 BU/mL for at least 2 consecutive measurements 2. FVIII recovery 66% of the predefined reference value of 1.5% IU/kg BW 3. FVIII half-life 6 h The primary endpoint for Group 3 is to evaluate the ABR compared with the ABR in Group 1 and Group 2.

Momentos temporales de evaluación primaria

No aportado

Objetivo Secundario

Secondary objectives for participants in Group 1 and Group 2 include: 1.Time to achieve ITI outcome 2.Use of emicizumab, aPCC, rFVIIa during ITI 3.Rate of FVIII inhibitor relapses during a follow-up period in participants who have achieved complete ITI success Secondary objectives for all 3 groups include the assessment of: 1.Frequency and severity of all bleeding episodes (BEs), all treated BEs, all spontaneous BEs, all joint BEs, and target joint BEs over time (3 bleeds in the same joint within 24 weeks) 2.Number of infusions required to control BEs 3.Frequency and severity of bleeding during and after surgical procedures 4.Proportion of participants experiencing adverse drug reactions (ADRs) against haemophilia treatment 5.Thrombotic events (location, treatment, outcome) 6.Treatment costs

Variables de Evaluación Secundaria

For participants in Group 1 and Group 2: 1.Time to achieve ITI outcome 2.Use of emicizumab, aPCC, rFVIIa during ITI 3.Rate of FVIII inhibitor relapses during a follow-up period in participants who have achieved complete ITI success

For participants in all 3 groups: 1.Frequency and severity of all bleeding episodes (BEs), all treated BEs, all spontaneous BEs, all joint BEs, and target joint BEs over time (3 bleeds in the same joint within 24 weeks)

2.Number of infusions required to control BEs 3.Frequency and severity of bleeding during and after surgical procedures
For participants in all 3 groups: 4.Proportion of participants experiencing ADRs 5.Thrombotic events (location, treatment, outcome) 6.Treatment costs

Momentos temporales de evaluación secundaria

No aportado

Criterios de Inclusión

1.Participants can be of any age at the time of enrolment into the trial. 2.Male persons with hemophilia A (HA), of any severity, who have a historical inhibitor titre 0.6 BU/mL, including those who have failed previous ITI attempt(s) 3.Persons undergoing ITI with NuwIQ®, octanate® or wilate® or undergoing ITI with NuwIQ®, octanate® or wilate® and receiving prophylactic therapy with emicizumab, aPCC or rFVIIa 4.Participants or participants parent(s)/legal guardian(s) must be capable of giving signed informed consent and be able to understand the trial documents

Criterios de Exclusión

1.Participants are excluded from the trial if any coagulation disorder other than HA is diagnosed 2.Partly retrospective patients will be excluded if detailed documentation on treatment, all BEs, inhibitor titres and FVIII levels is not available for the retrospective period

Calendario

(Última actualización: 22/10/2025)

Autorización 09/12/2020	Inicio de Ensayo 27/04/2021	Inclusión Primer Paciente 12/05/2021	Interrumpido No aportado	Reiniciado No aportado
Fin de reclutamiento No aportado	Fin prematuro (España) No aportado	Fin prematuro (Global) No aportado	Fin del ensayo en España No aportado	Fin del ensayo global No aportado

Promotor

HZRM Haemophilie-Zentrum Rhein Main GmbH Germany

Stresemannallee 15Sachsenhausen

Contact Person

Carmen Escuriola

+14047851112

carmen.escuriola@hzrm.de

Monetary support: N/A

Tipo de promotor: No comercial

Ceim

CEIm Hospital Universitari Vall d Hebron

Passeig de la Vall d.Hebron, 119-129 - Edificio Materno-Infantil, planta 13 08035 Barcelona

ceic@vhir.org

934894010

Centros

No iniciado (--/--/----)	Hospital General Universitario Dr. Balmis Alicante ALICANTE Dept of Haemostasis and Thrombosis	Activo (27/04/2021)	HOSPITAL UNIVERSITARI VALL D'HEBRON Barcelona BARCELONA Servicio de Hematología y Hemoterapia
	Hospital Universitario San Juan De Alicante Sant Joan D'alacant ALICANTE Hematology Department		Hospital Universitario Virgen Del Rocio Sevilla SEVILLA Servicio de Hematología y Hemoterapia

Medicamentos

FEIBA 500 E Pulver und Lösungsmittel zur Herstellung einer Infusionslösung.

SOLUTION FOR INFUSION

INTRAVENOUS

Código ATC: B02BD03 - ACTIVIDAD QUE SOBREPASA EL INHIBIDOR DEL FACTOR VIII

Principios Activos: N/A

Experimental

CEVENFACTA 5 mg (225 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD08 - FACTOR VIIA DE LA COAGULACION

Principios Activos: N/A

Experimental

Nuwiq 250 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION

Principios Activos: N/A

Experimental

OCTANATE 250 Pulver und Lösungsmittel zur Herstellung einer Injektionslösung

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION

Principios Activos: N/A

Experimental

Nuwiq 2500 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION

Principios Activos: N/A

Experimental

Wilate 500, 500 I.E. VWF/500 I.E. FVIII, Pulver und Lösungsmittel zur Herstellung einer intravenösen Injektionslösung.

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD06 - FACTOR VON WILLEBRAND Y FACTOR VIII DE LA COAGULACION EN COMBINACION

Principios Activos: N/A

Experimental

NovoSeven 8 mg (400 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD08 - FACTOR VIIA DE LA COAGULACION

Principios Activos: N/A

NovoSeven 5 mg (250 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD08 - FACTOR VIIA DE LA COAGULACION

Principios Activos: N/A

Experimental

Experimental

NovoSeven 2 mg (100 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD08 - FACTOR VIIA DE LA COAGULACION

Principios Activos: N/A

Experimental

Nuwiq 1500 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION

Principios Activos: N/A

Experimental

Hemlibra 30 mg/mL solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS USE

Código ATC: B02BX06 - EMICIZUMAB

Principios Activos: N/A

Experimental

Wilate 1000, 1000 I.E. VWF/1000 I.E. FVIII, Pulver und Lösungsmittel zur Herstellung einer intravenösen Injektionslösung.

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD06 - FACTOR VON WILLEBRAND Y FACTOR VIII DE LA COAGULACION EN COMBINACION

Principios Activos: N/A

Experimental

Nuwiq 2000 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION

Principios Activos: N/A

Experimental

Nuwiq 1000 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION

Principios Activos: N/A

Experimental

Hemlibra 150 mg/mL solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS USE

OCTANATE 1000 Pulver und Lösungsmittel zur Herstellung einer Injektionslösung

Código ATC: B02BX06 - EMICIZUMAB

Principios Activos: N/A

Experimental

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION

Principios Activos: N/A

Experimental

Nuwiq 3000 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION

Principios Activos: N/A

Experimental

CEVENFACTA 2 mg (90 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD08 - FACTOR VIIA DE LA COAGULACION

Principios Activos: N/A

Experimental

CEVENFACTA 1 mg (45 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD08 - FACTOR VIIA DE LA COAGULACION

Principios Activos: N/A

Experimental

Hemlibra 150 mg/mL solution for injection

SUSPENSION FOR INJECTION

SUBCUTANEOUS USE

Código ATC: B02BX06 - EMICIZUMAB

Principios Activos: N/A

Experimental

FEIBA 1000 E Pulver und Lösungsmittel zur Herstellung einer Infusionslösung

SOLUTION FOR INFUSION

INTRAVENOUS

Código ATC: B02BD03 - ACTIVIDAD QUE SOBREPASA EL INHIBIDOR DEL FACTOR VIII

Principios Activos: N/A

Experimental

Nuwiq 500 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION

Principios Activos: N/A

Experimental

Hemlibra 150 mg/mL solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS USE

Código ATC: B02BX06 - EMICIZUMAB

Principios Activos: N/A

Experimental

Nuwiq 4000 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION

Principios Activos: N/A

Experimental

OCTANATE 500 Pulver und Lösungsmittel zur Herstellung einer Injektionslösung

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD02 - FACTOR VIII DE LA COAGULACION

Principios Activos: N/A

Experimental

NovoSeven 1 mg (50 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

Código ATC: B02BD08 - FACTOR VIIA DE LA COAGULACION

Principios Activos: N/A

Experimental

Hemlibra 30 mg/mL solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS USE

Código ATC: B02BX06 - EMICIZUMAB

Principios Activos: N/A

Experimental

Hemlibra 150 mg/mL solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS USE

Código ATC: B02BX06 - EMICIZUMAB

Principios Activos: N/A

Experimental

FEIBA 2500 E Pulver und Lösungsmittel zur Herstellung einer Infusionslösung.

SOLUTION FOR INFUSION

INTRAVENOUS

Código ATC: B02BD03 - ACTIVIDAD QUE SOBREPASA EL INHIBIDOR DEL FACTOR VIII

Principios Activos: N/A

Experimental

Sin resultados

An international investigator initiated trial to capture different approaches in the treatment of Haemophilia A Patients With FVIII Inhibitors

State	Type of participants	Age Ranges
Recruiting	Incapable subjects of giving consent	Less than 18 , Older than 64 , Adults (18-64 years)
Gender	Phases	Expected Participants
Men	Phase IV	101
Results	Low level of intervention	Rare disease
No results	Yes	Yes
Geographic coverage	Areas of the study	Advanced therapy
Undetermined	prophylaxis, treatment, safety, effectiveness, pharmacokinetics, pharmacogenetics, pharmacoeconomic	NO

Information

Identifier

2024-516741-39-00 (CTIS)

Protocol Code

MOTIVATE

Transitioned 2019-003427-38

Therapeutic area

Diseases [C] - Hemic and Lymphatic Diseases [C15]

Investigated Disease

Haemophilia A

Scientific Title

MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A An International Low-Interventional Pragmatic

Investigator Initiated Trial

Rationale

Not provided

Main Objective

The primary objective for Groups 1 and 2 is to evaluate ITI outcomes as determined by achievement of the following ITI criteria: 1. Inhibitor titre < 0.6 Bethesda units (BU)/mL for at least 2 consecutive measurements 2. FVIII recovery 66% of the predefined reference value of 1.5% international units (IU)/kg body weight (BW) 3. FVIII half-life 6 h The primary objective for Group 3 is to evaluate the annualised bleeding rate (ABR) compared with the ABR in Group 1 and Group 2.

Primary Endpoints

The primary endpoint in Group 1 and Group 2 is to evaluate ITI outcome as determined by achievement of the following ITI criteria: 1. Inhibitor titre < 0.6 BU/mL for at least 2 consecutive measurements 2. FVIII recovery 66% of the predefined reference value of 1.5% IU/kg BW 3. FVIII half-life 6 h The primary endpoint for Group 3 is to evaluate the ABR compared with the ABR in Group 1 and Group 2.

Temporary moments of secondary assessment

Not provided

Secondary Objective

Secondary objectives for participants in Group 1 and Group 2 include: 1.Time to achieve ITI outcome 2.Use of emicizumab, aPCC, rFVIIa during ITI 3.Rate of FVIII inhibitor relapses during a follow-up period in participants who have achieved complete ITI success Secondary objectives for all 3 groups include the assessment of: 1.Frequency and severity of all bleeding episodes (BEs), all treated BEs, all spontaneous BEs, all joint BEs, and target joint BEs over time (3 bleeds in the same joint within 24 weeks) 2.Number of infusions required to control BEs 3.Frequency and severity of bleeding during and after surgical procedures 4.Proportion of participants experiencing adverse drug reactions (ADRs) against haemophilia treatment 5.Thrombotic events (location, treatment, outcome) 6.Treatment costs

Secondary Endpoints

For participants in Group 1 and Group 2: 1.Time to achieve ITI outcome 2.Use of emicizumab, aPCC, rFVIIa during ITI 3.Rate of FVIII inhibitor relapses during a follow-up period in participants who have achieved complete ITI success

For participants in all 3 groups: 1.Frequency and severity of all bleeding episodes (BEs), all treated BEs, all spontaneous BEs, all joint BEs, and target joint BEs over time (3 bleeds in the same joint within 24 weeks)

2.Number of infusions required to control BEs 3.Frequency and severity of bleeding during and after surgical procedures
For participants in all 3 groups: 4.Proportion of participants experiencing ADRs 5.Thrombotic events (location, treatment, outcome) 6.Treatment costs

Temporary moments of secondary assessment

Not provided

Inclusion criteria

1.Participants can be of any age at the time of enrolment into the trial. 2.Male persons with hemophilia A (HA), of any severity, who have a historical inhibitor titre 0.6 BU/mL, including those who have failed previous ITI attempt(s) 3.Persons undergoing ITI with NuwIQ®, octanate® or wilate® or undergoing ITI with NuwIQ®, octanate® or wilate® and receiving prophylactic therapy with emicizumab, aPCC or rFVIIa 4.Participants or participants parent(s)/legal guardian(s) must be capable of giving signed informed consent and be able to understand the trial documents

Exclusion criteria

1.Participants are excluded from the trial if any coagulation disorder other than HA is diagnosed 2.Partly retrospective patients will be excluded if detailed documentation on treatment, all BEs, inhibitor titres and FVIII levels is not available for the retrospective period

Calendar

(Last Update: 22/10/2025)

Authorization 09/12/2020	Start of Trial 27/04/2021	First patient inclusion 12/05/2021	Halted Not aported	Restarted Not aported
End of recruitment Not aported	Premature end (Spain) Not aported	Premature End (Global) Not aported	Trial end (Spain) Not aported	Trial end (Global) Not aported

Sponsor

HZRM Haemophilie-Zentrum Rhein Main GmbH Germany

Stresemannallee 15Sachsenhausen

Contact Person

Carmen Escuriola

+14047851112

carmen.escuriola@hzrm.de

Monetary support: N/A

Sponsor type: No commercial

Ceim

CEIm Hospital Universitari Vall d Hebron

Passeig de la Vall d.Hebron, 119-129 - Edificio Materno-Infantil, planta 13 08035 Barcelona

ceic@vhir.org

934894010

Sites

not initialized (---/---/----)	Hospital General Universitario Dr. Balmis Alicante ALICANTE Dept of Haemostasis and Thrombosis
Active (27/04/2021)	HOSPITAL UNIVERSITARI VALL D'HEBRON Barcelona BARCELONA Servicio de Hematología y Hemoterapia
not initialized (---/---/----)	Hospital Universitario San Juan De Alicante Sant Joan D'alacant ALICANTE Hematology Department
not initialized (09/12/2020)	Hospital Universitario Virgen Del Rocio Sevilla SEVILLA Servicio de Hematología y Hemoterapia

Medication

FEIBA 500 E Pulver und Lösungsmittel zur Herstellung einer Infusionslösung.

SOLUTION FOR INFUSION

INTRAVENOUS

ATC code: B02BD03 - ACTIVIDAD QUE SOBREPASA EL INHIBIDOR DEL FACTOR VIII

Active Principles: N/A

Experimental

CEVENFACTA 5 mg (225 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD08 - FACTOR VIIA DE LA COAGULACION

Active Principles: N/A

Experimental

Nuwiq 250 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION

Active Principles: N/A

Experimental

OCTANATE 250 Pulver und Lösungsmittel zur Herstellung einer Injektionslösung

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION

Active Principles: N/A

Experimental

Nuwiq 2500 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION

Active Principles: N/A

Experimental

Wilate 500, 500 I.E. VWF/500 I.E. FVIII, Pulver und Lösungsmittel zur Herstellung einer intravenösen Injektionslösung.

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD06 - FACTOR VON WILLEBRAND Y FACTOR VIII DE LA COAGULACION EN COMBINACION

Active Principles: N/A

Experimental

NovoSeven 8 mg (400 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD08 - FACTOR VIIA DE LA COAGULACION

Active Principles: N/A

NovoSeven 5 mg (250 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD08 - FACTOR VIIA DE LA COAGULACION

Active Principles: N/A

Experimental

Experimental

NovoSeven 2 mg (100 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD08 - FACTOR VIIA DE LA COAGULACION

Active Principles: N/A

Experimental

Nuwiq 1500 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION

Active Principles: N/A

Experimental

Hemlibra 30 mg/mL solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS USE

ATC code: B02BX06 - EMICIZUMAB

Active Principles: N/A

Experimental

Wilate 1000, 1000 I.E. VWF/1000 I.E. FVIII, Pulver und Lösungsmittel zur Herstellung einer intravenösen Injektionslösung.

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD06 - FACTOR VON WILLEBRAND Y FACTOR VIII DE LA COAGULACION EN COMBINACION

Active Principles: N/A

Experimental

Nuwiq 2000 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION

Active Principles: N/A

Experimental

Nuwiq 1000 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION

Active Principles: N/A

Experimental

Hemlibra 150 mg/mL solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS USE

OCTANATE 1000 Pulver und Lösungsmittel zur Herstellung einer Injektionslösung

ATC code: B02BX06 - EMICIZUMAB

Active Principles: N/A

Experimental

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION

Active Principles: N/A

Experimental

Nuwiq 3000 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION

Active Principles: N/A

Experimental

CEVENFACTA 2 mg (90 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD08 - FACTOR VIIA DE LA COAGULACION

Active Principles: N/A

Experimental

CEVENFACTA 1 mg (45 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD08 - FACTOR VIIA DE LA COAGULACION

Active Principles: N/A

Experimental

Hemlibra 150 mg/mL solution for injection

SUSPENSION FOR INJECTION

SUBCUTANEOUS USE

ATC code: B02BX06 - EMICIZUMAB

Active Principles: N/A

Experimental

FEIBA 1000 E Pulver und Lösungsmittel zur Herstellung einer Infusionslösung

SOLUTION FOR INFUSION

INTRAVENOUS

ATC code: B02BD03 - ACTIVIDAD QUE SOBREPASA EL INHIBIDOR DEL FACTOR VIII

Active Principles: N/A

Experimental

Nuwiq 500 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION

Active Principles: N/A

Experimental

Hemlibra 150 mg/mL solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS USE

ATC code: B02BX06 - EMICIZUMAB

Active Principles: N/A

Experimental

Nuwiq 4000 IU powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION

Active Principles: N/A

Experimental

OCTANATE 500 Pulver und Lösungsmittel zur Herstellung einer Injektionslösung

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD02 - FACTOR VIII DE LA COAGULACION

Active Principles: N/A

Experimental

NovoSeven 1 mg (50 KIU) powder and solvent for solution for injection

SOLUTION FOR INJECTION

INTRAVENOUS

ATC code: B02BD08 - FACTOR VIIA DE LA COAGULACION

Active Principles: N/A

Experimental

Hemlibra 30 mg/mL solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS USE

ATC code: B02BX06 - EMICIZUMAB

Active Principles: N/A

Experimental

Hemlibra 150 mg/mL solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS USE

ATC code: B02BX06 - EMICIZUMAB

Active Principles: N/A

Experimental

FEIBA 2500 E Pulver und Lösungsmittel zur Herstellung einer Infusionslösung.

SOLUTION FOR INFUSION

INTRAVENOUS

ATC code: B02BD03 - ACTIVIDAD QUE SOBREPASA EL INHIBIDOR DEL FACTOR VIII

Active Principles: N/A

Experimental

No results